Group 1 - The core viewpoint of the news is that Heptares Therapeutics has entered into a global strategic collaboration agreement with Otsuka Pharmaceutical Co., Ltd. to advance the development of HBM7020, a bispecific T-cell engager for the treatment of autoimmune diseases [1] - Under the agreement, Otsuka is granted exclusive rights to develop, manufacture, and commercialize HBM7020 globally, excluding Greater China [1] - The company is entitled to receive a total of $47 million in upfront and near-term payments, with potential milestone payments of up to $623 million upon achieving specific development and commercialization milestones, along with tiered royalties on future net sales [1] Group 2 - HBM7020 is a bispecific antibody generated using the company's fully human HBICE® dual antibody technology and Harbour Mice® platform, designed to effectively activate T-cells and kill target cells by cross-linking them with BCMA and CD3 on the cell surface [2] - The antibody enhances cell targeting by binding to dual BCMA binding sites and optimizes CD3 activity to reduce cytokine release syndrome (CRS), showing strong cellular activity applicable to immune and tumor diseases [2] - In August 2023, HBM7020 received approval for an Investigational New Drug (IND) application from the National Medical Products Administration (NMPA) in China to initiate Phase I clinical trials for cancer [2]
和铂医药-B(02142)与大冢订立全球战略合作协议,以推进用于治疗自身免疫性疾病的BCMAxCD3双特异性T细胞衔接器HBM7020